Emylcamate

Summary

Emylcamate (marketed as Striatran by Merck) is an anxiolytic and muscle relaxant. It was patented in the US in 1961 (US Patent 2,972,564) and advertised for the treatment of anxiety and tension. It was claimed to be superior to meprobamate, which would eventually replace emylcamate.

Emylcamate
Clinical data
ATC code
Legal status
Legal status
Identifiers
  • 3-methyl-3-pentanol carbamate
CAS Number
  • 78-28-4 checkY
PubChem CID
  • 6526
DrugBank
  • DB13572 checkY
ChemSpider
  • 6278 checkY
UNII
  • KCJ747D3R4
KEGG
  • D07317 checkY
ChEBI
  • CHEBI:134769
ChEMBL
  • ChEMBL2104208 checkY
CompTox Dashboard (EPA)
  • DTXSID40228645 Edit this at Wikidata
ECHA InfoCard100.001.002 Edit this at Wikidata
Chemical and physical data
FormulaC7H15NO2
Molar mass145.202 g·mol−1
3D model (JSmol)
  • Interactive image
  • O=C(OC(C)(CC)CC)N
  • InChI=1S/C7H15NO2/c1-4-7(3,5-2)10-6(8)9/h4-5H2,1-3H3,(H2,8,9) checkY
  • Key:SLWGJZPKHAXZQL-UHFFFAOYSA-N checkY
 ☒NcheckY (what is this?)  (verify)

A study of the drug's effects in mice was done in 1959. It concluded that at 50 mg/kg emylcamate gave a 63% decrease in motor activity compared with meprobamate's 32% decrease, a doubling in effective potency. The therapeutic index in mice was also established:

Meprobamate Emylcamate Effect
175 123 ED50 (mg/kg)
600 550 LD50 (mg/kg)
3.4 4.4 Therapeutic index

Emylcamate also has a faster intra-parenteral onset than meprobamate, 3 minutes compared with 35. [2]

References edit

  1. ^ Anvisa (2023-03-31). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 2023-04-04). Archived from the original on 2023-08-03. Retrieved 2023-08-16.
  2. ^ Melander B (1959). "Emylcamate, A Potent Tranquillizing Relaxant". Journal of Medicinal and Pharmaceutical Chemistry. 1 (5): 443–457. doi:10.1021/jm50006a003.

Further reading edit

  • Shorter E (August 2004). "Olhando para trás: um novo caminho possível para a descoberta de drogas em psicofarmacologia" [Looking back: a new possible path for drug discovery in psychopharmacology.]. Revista de Psiquiatria do Rio Grande do Sul (in Portuguese). 26 (2): 196–203. doi:10.1590/S0101-81082004000200009.

External links edit

  • "Emylcamate". The Comparative Toxicogenomics Database.
  • "Emylcamate". BIAM (in French). Archived from the original on 2022-09-26. Retrieved 2005-12-22.